– Sec Filing
Baird Initiates Coverage On Instil Bio with Outperform Rating, Announces Price Target of $34
Baird analyst Jack Allen initiates coverage on Instil Bio (NASDAQ:TIL) with a Outperform rating and announces Price Target of $34.
Related Posts
Why Tilray Shares Are Trading Higher Today
Tilray Inc (NASDAQ: TLRY) is trading significantly higher Monday following reports of a Republican-led marijuana legalization bill.
Sphere 3D Shares Halted On Circuit Breaker To Upside; Seeking Alpha Reports Elon Musk Will Likely Join M&A Partner Gryphon Digital Mining As Board Member After Merger
https://seekingalpha.com/instablog/49951726-biotechplayer123/5643963-elon-musk-will-likely-join-gryphon-digital-mining-board-member-after-merger-sphere-3d-in-4q21
CytomX Therapeutics Q4 EPS $(0.40) Misses $(0.28) Estimate, Sales $19.73M Miss $24.51M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.28) by 42.86 percent. This is a 29.03 percent decrease over losses of $(0.31) per share